BioSpace News Archive

In vivo toxicology is the study of toxic effects of chemical substances performed on living organisms, e.g. laboratory animal. Researchers conduct in vivo testing for determining the reduction in the toxic effects of reduced risk products.

Zdravlje represents a solid foundation upon which a leading international pharmaceutical platform will be built over the coming years

Tetra Bio-Pharma Inc., a biopharmaceutical pioneer in immunomodulator drug discovery and development announce they have received a notice of compliance for its Drug Establishment License following an audit by the Drug GMP Inspection Program of Health Canada.

Hemogenyx Pharmaceuticals plc, the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to issue an update on negotiations regarding the future development of its leading product candidate CDX bispecific antibody for the treatment of acute myeloid leukemia.

Yingli Pharma announce promising topline results of a Phase II registration study for treatment of relapsed/refractory follicular lymphoma with the once daily oral PI3Kδ inhibitor, linperlisib

Celon Pharma S.A. announced the successful completion of a Phase 1 trial of its second generation GPR40 agonist, CPL’280.

Tauriga Sciences, Inc., a revenue generating, diversified life sciences company, with a proprietary line of CBD & CBG infused Supplement chewing gums, additional product offerings, as well as an ongoing Pharmaceutical Development initiative, announced that it has successfully registered on BidNet Direct and is actively bidding on U.S. Government contract.

Baudax Bio, Inc. (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that the Compensation Committee of Baudax Bio’s Board of Directors approved an inducement grant of stock options to purchase an aggregate of 7,500 shares of Baudax Bio’s common stock and restricted stock units covering 2,000 shares of Baudax Bio’s common stock

Transaction includes TIBSOVO®, co-commercialization responsibilities for Bristol Myers Squibb’s IDHIFA® as well as a strong oncology pipeline of Phase 3 and early-stage assets

Castle Biosciences , Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced it will collaborate with the Melanoma Research Foundation (MRF) to present “Ask the Expert” Managing Melanoma, a webinar series, throughout the month of April.